New type of molecular switch could turn up the volume on bowel cancer treatment

November 5, 2012

(Medical Xpress)—A new type of molecular switch can boost common chemotherapy drugs to destroy bowel cancer cells, according to research presented today (Monday) at the NCRI Cancer Conference in Liverpool.

Scientists at the University of Dundee examined hundreds of molecules which may help to predict whether bowel can be successfully treated with chemotherapy.

Many bowel cancer patients are treated with a drug called 5-fluorouracil, or 5-FU, but not all patients respond well. It is difficult to predict which patients will be successfully treated.

The team revealed in laboratory experiments that blocking a called miR-224 'tricks' bowel cancer cells containing a healthy gene called K-RAS into behaving like cells with a damaged form of the gene.

K-RAS usually controls the normal growth of healthy bowel cells. But faulty versions of K-RAS are found in one third of bowel cancers, particularly in fast-growing cancers with poor survival.

The research showed that common drugs, 5-FU and , were more effective in treating bowel cancer cells with damaged forms of K-RAS, and bowel cancer cells with healthy K-RAS in which the miR-224 switch had been blocked.

Lead author, Dr Gillian Smith, at the University of Dundee, said: "Our research reveals that changing the behaviour of K-RAS boosts the effect of certain drugs to kill bowel .

"This research is at an early stage, but if we're able to prove these results in larger studies, the findings could provide new scope for bowel cancer treatments targeting the K-RAS gene. Our findings are particularly interesting because there is already a test available in the clinic that can identify which patients have a faulty version of K-RAS."

Bowel cancer is one of the most commonly diagnosed cancers in the UK with more than 41,000 people diagnosed with the disease in the UK each year.

Dr Jane Cope, director of the NCRI, said: "This is exciting research that adds to the dramatic progress made over the past thirty years in tackling .

"People diagnosed today are twice as likely to survive for at least ten years as those diagnosed in the 1970s and we hope that these findings will one day help scientists develop better ways to treat and monitor the disease in the future - ultimately increasing survival from cancer."

Explore further: Bowel screening helps to detect early cancers before they become deadly, study finds

Related Stories

Bowel screening helps to detect early cancers before they become deadly, study finds

November 5, 2012
(Medical Xpress)—Bowel screening is detecting more cancers when they are less mature and have less aggressive biological characteristics according to new research presented at the NCRI Cancer Conference in Liverpool this ...

Scientists discover how iron levels and a faulty gene cause bowel cancer

August 9, 2012
High levels of iron could raise the risk of bowel cancer by switching on a key pathway in people with faults in a critical anti-cancer gene, according to a study published in Cell Reports today.

Screening helps early diagnosis of bowel cancer

June 18, 2012
(Medical Xpress) -- Patients who attend bowel screening are more likely to be diagnosed with bowel cancer at an early stage - when there is a better chance of survival - than those who wait until they have symptoms of the ...

Poor men more likely to die from bowel cancer

November 7, 2011
(Medical Xpress) -- Deprived men are more likely to die from bowel cancer than men from the most affluent section of society, new research presented at the NCRI Cancer Conference in Liverpool this week shows.

Bowel screening reduces cancer deaths by more than 25 per cent

November 9, 2011
(Medical Xpress) -- Bowel screening reduces the number of deaths from bowel cancer in Scotland by more than 25 per cent, according to research* presented at the National Cancer Research Institute (NCRI) Cancer Conference ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.